EUVIMEDEUVIMED entdecken
Open Access

Therapeutic Inhibition of LincRNA-p21 Protects Against Cardiac Hypertrophy

Yi Wang iD, Mingming Zhang iD, Rong Wang, Jing Lin iD, Qing Ma iD, Haipeng Guo, Huihui Huang iD, Zhuomin Liang iD, Yangpo Cao, Xiaoran Zhang iD, Yao Wei Lu iD, Jianming Liu und 7 weitere

Circulation Research · 2024

DOI: 10.1161/circresaha.123.323356 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Circulation Research, 2024. Verfasst von Yi Wang und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Boston Children's Hospital (Y.W., M.Z., R.W., J. Lin, Q.M., H.G., Z.L., Y.C., X.Z., Y.W.L., J. Liu, F.X., H.Y., Z.-P.H., W.…. Hauptthemen laut MEDLINE: Cardiomegaly, Mice, Knockout, RNA, Long Noncoding. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Cardiac hypertrophy is an adaptive response to pressure overload aimed at maintaining cardiac function. However, prolonged hypertrophy significantly increases the risk of maladaptive cardiac remodeling and heart failure. Recent studies have implicated long noncoding RNAs in cardiac hypertrophy and cardiomyopathy, but their significance and mechanism(s) of action are not well understood. METHODS: We measured lincRNA-p21 RNA and H3K27ac levels in the hearts of dilated cardiomyopathy patients. We assessed the functional role of lincRNA-p21 in basal and surgical pressure-overload conditions using loss-of-function mice. Genome-wide transcriptome analysis revealed dysregulated genes and pathways. We labeled proteins in proximity to full-length lincRNA-p21 using a novel BioID2-based system. We immunoprecipitated lincRNA-p21-interacting proteins and performed cell fractionation, ChIP-seq (chromatin immunoprecipitation followed by sequencing), and co-immunoprecipitation to investigate molecular interactions and underlying mechanisms. We used GapmeR antisense oligonucleotides to evaluate the therapeutic potential of lincRNA-p21 inhibition in cardiac hypertrophy and associated heart failure. RESULTS: lincRNA-p21 was induced in mice and humans with cardiomyopathy. Global and cardiac-specific lincRNA-p21 knockout significantly suppressed pressure overload-induced ventricular wall thickening, stress marker elevation, and deterioration of cardiac function. Genome-wide transcriptome analysis and transcriptional network analysis revealed that lincRNA-p21 acts in trans to stimulate the NFAT/MEF2 (nuclear factor of activated T cells/myocyte enhancer factor-2) pathway. Mechanistically, lincRNA-p21 is bound to the scaffold protein KAP1 (KRAB-associated protein-1). lincRNA-p21 cardiac-specific knockout suppressed stress-induced nuclear accumulation of KAP1, and KAP1 knockdown attenuated cardiac hypertrophy and NFAT activation. KAP1 positively regulates pathological hypertrophy by physically interacting with NFATC4 to promote the overactive status of NFAT/MEF2 signaling. GapmeR antisense oligonucleotide depletion of lincRNA-p21 similarly inhibited cardiac hypertrophy and adverse remodeling, highlighting the therapeutic potential of inhibiting lincRNA-p21 . CONCLUSIONS: These findings advance our understanding of the functional significance of stress-induced long noncoding RNA in cardiac hypertrophy and demonstrate the potential of lincRNA-p21 as a novel therapeutic target for cardiac hypertrophy and subsequent heart failure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CardiomegalyMice, KnockoutRNA, Long NoncodingAnimalsHumansMaleMiceCardiomyopathy, DilatedMice, Inbred C57BLMyocytes, CardiacVentricular Remodeling

Stichwörter der Autor:innen

RNA, long noncodinggene expression profilingheart failurehypertrophyventricular remodeling

Substanzen

RNA, Long NoncodinglincRNA-p21, mouse

Autor:innen und Institutionen

  • Department of Cardiology, Boston Children's Hospital (Y.W., M.Z., R.W., J. Lin, Q.M., H.G., Z.L., Y.C., X.Z., Y.W.L., J. Liu, F.X., H.Y., Z.-P.H., W.T.P., D.-Z.W.), Harvard Medical School, Boston, MA.
  • Department of Cardiology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, China (M.Z.).
  • Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China (R.W.).
  • School of Public Health, Xi'an Jiaotong University, China (J. Lin).
  • Department of Critical Care and Emergency Medicine, Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health, Qilu Hospital, Cheeloo College of Medi…
  • Division of Nephrology, Beth Israel Deaconess Medical Center (H.H.), Harvard Medical School, Boston, MA.

ORCID-Profile: Yi Wang, Mingming Zhang, Jing Lin, Qing Ma, Huihui Huang, Zhuomin Liang, Xiaoran Zhang, Yao Wei Lu, Feng Xiao, Hualin Yan, Nadya Dimitrova, Zhan-Peng Huang, John D Mably, William T Pu, Da-Zhi Wang

Förderung

  • NHLBI NIH HHS

Zitieren

APA

Wang, Y., Zhang, M., Wang, R., Lin, J., Ma, Q., Guo, H., Huang, H., Liang, Z., Cao, Y., Zhang, X., Lu, Y. W., Liu, J., Xiao, F., Yan, H., Dimitrova, N., Huang, Z. P., Mably, J. D., Pu, W. T., & Wang, D. Z. (2024). Therapeutic Inhibition of LincRNA-p21 Protects Against Cardiac Hypertrophy. Circulation Research. https://doi.org/10.1161/circresaha.123.323356

Vancouver

Wang Y, Zhang M, Wang R, Lin J, Ma Q, Guo H, et al. Therapeutic Inhibition of LincRNA-p21 Protects Against Cardiac Hypertrophy. Circulation Research. 2024. doi:10.1161/circresaha.123.323356

BibTeX
@article{Wang2024,
  author = {Wang, Yi and Zhang, Mingming and Wang, Rong and Lin, Jing and Ma, Qing and Guo, Haipeng and Huang, Huihui and Liang, Zhuomin and Cao, Yangpo and Zhang, Xiaoran and Lu, Yao Wei and Liu, Jianming and Xiao, Feng and Yan, Hualin and Dimitrova, Nadya and Huang, Zhan-Peng and Mably, John D and Pu, William T and Wang, Da-Zhi},
  title = {Therapeutic Inhibition of LincRNA-p21 Protects Against Cardiac Hypertrophy},
  journal = {Circulation Research},
  year = {2024},
  doi = {10.1161/circresaha.123.323356}
}
Kostenlos starten →